Abstract
The study aims to develop pharmacokinetic-pharmacodynamic (PK-PD) models of the antibiotics rifampicin, isoniazid, pyrazinamide and ethambutol in macrophages derived from human monocytes of THP-1 lineage infected and not infected with M. tuberculosis H37Rv strains. Macrophage PK-PD data from antibiotics will be incorporated into population pharmacokinetic models in plasma of tuberculosis …